Malaysia
· Delayed Price · Currency is MYR Duopharma Biotech Berhad Statistics
Total Valuation
KLSE:DPHARMA has a market cap or net worth of MYR 1.20 billion. The enterprise value is 1.43 billion.
| Market Cap | 1.20B |
| Enterprise Value | 1.43B |
Important Dates
The last earnings date was Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | Sep 8, 2025 |
Share Statistics
KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has decreased by -0.12% in one year.
| Current Share Class | 961.94M |
| Shares Outstanding | 961.94M |
| Shares Change (YoY) | -0.12% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 72.11% |
| Float | 450.08M |
Valuation Ratios
The trailing PE ratio is 14.39 and the forward PE ratio is 12.08. KLSE:DPHARMA's PEG ratio is 0.61.
| PE Ratio | 14.39 |
| Forward PE | 12.08 |
| PS Ratio | 1.34 |
| PB Ratio | 1.62 |
| P/TBV Ratio | 1.71 |
| P/FCF Ratio | 15.01 |
| P/OCF Ratio | 10.82 |
| PEG Ratio | 0.61 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.56, with an EV/FCF ratio of 17.82.
| EV / Earnings | 17.10 |
| EV / Sales | 1.58 |
| EV / EBITDA | 8.56 |
| EV / EBIT | 11.32 |
| EV / FCF | 17.82 |
Financial Position
The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.66.
| Current Ratio | 2.54 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 2.96 |
| Debt / FCF | 6.16 |
| Interest Coverage | 5.26 |
Financial Efficiency
Return on equity (ROE) is 11.60% and return on invested capital (ROIC) is 6.40%.
| Return on Equity (ROE) | 11.60% |
| Return on Assets (ROA) | 5.62% |
| Return on Invested Capital (ROIC) | 6.40% |
| Return on Capital Employed (ROCE) | 11.14% |
| Revenue Per Employee | 460,234 |
| Profits Per Employee | 42,666 |
| Employee Count | 1,957 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.17 |
Taxes
In the past 12 months, KLSE:DPHARMA has paid 23.95 million in taxes.
| Income Tax | 23.95M |
| Effective Tax Rate | 22.29% |
Stock Price Statistics
The stock price has increased by +1.61% in the last 52 weeks. The beta is 0.22, so KLSE:DPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +1.61% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 44.15 |
| Average Volume (20 Days) | 417,580 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:DPHARMA had revenue of MYR 900.68 million and earned 83.50 million in profits. Earnings per share was 0.09.
| Revenue | 900.68M |
| Gross Profit | 342.62M |
| Operating Income | 126.08M |
| Pretax Income | 107.45M |
| Net Income | 83.50M |
| EBITDA | 163.24M |
| EBIT | 126.08M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 268.67 million in cash and 493.78 million in debt, giving a net cash position of -225.12 million or -0.23 per share.
| Cash & Cash Equivalents | 268.67M |
| Total Debt | 493.78M |
| Net Cash | -225.12M |
| Net Cash Per Share | -0.23 |
| Equity (Book Value) | 744.12M |
| Book Value Per Share | 0.77 |
| Working Capital | 491.62M |
Cash Flow
In the last 12 months, operating cash flow was 111.12 million and capital expenditures -30.99 million, giving a free cash flow of 80.13 million.
| Operating Cash Flow | 111.12M |
| Capital Expenditures | -30.99M |
| Free Cash Flow | 80.13M |
| FCF Per Share | 0.08 |
Margins
Gross margin is 38.04%, with operating and profit margins of 14.00% and 9.27%.
| Gross Margin | 38.04% |
| Operating Margin | 14.00% |
| Pretax Margin | 11.93% |
| Profit Margin | 9.27% |
| EBITDA Margin | 18.12% |
| EBIT Margin | 14.00% |
| FCF Margin | 8.90% |
Dividends & Yields
This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.40%.
| Dividend Per Share | 0.03 |
| Dividend Yield | 2.40% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 40.32% |
| Buyback Yield | 0.12% |
| Shareholder Yield | 2.50% |
| Earnings Yield | 6.94% |
| FCF Yield | 6.66% |
Stock Splits
The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.
| Last Split Date | Sep 6, 2021 |
| Split Type | Forward |
| Split Ratio | 1.3333333333 |
Scores
KLSE:DPHARMA has an Altman Z-Score of 2.74 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.74 |
| Piotroski F-Score | 7 |